NAVB — Navidea Biopharmaceuticals Share Price
Last trade - 00:00- $0.07m
- -$2.25m
- $0.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 114.85 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -1576177.05% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.17 | 0.66 | 0.92 | 0.53 | 0.07 | n/a | n/a | -48.49% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company’s business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. It has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).
Directors
- Alexander Cappello CHM (65)
- John Scott VCH (66)
- Michel Mikhail OTH (67)
- Michael Rosol OTH (53)
- Amit Bhalla IND (47)
- Malcolm Witter IND (67)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- April 28th, 1988
- Public Since
- November 10th, 1992
- No. of Shareholders
- 373
- No. of Employees
- 11
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 100,084,385
- Address
- 4100 Horizons Drive, Suite 205, COLUMBUS, 43220
- Web
- https://www.navidea.com/
- Phone
- +1 6147937500
- Auditors
- Marcum LLP
Upcoming Events for NAVB
Similar to NAVB
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 22:13 UTC, shares in Navidea Biopharmaceuticals are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Navidea Biopharmaceuticals last closed at $0.00 and the price had moved by -98% over the past 365 days. In terms of relative price strength the Navidea Biopharmaceuticals share price has underperformed the S&P500 Index by -98.15% over the past year.
The overall consensus recommendation for Navidea Biopharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNavidea Biopharmaceuticals does not currently pay a dividend.
Navidea Biopharmaceuticals does not currently pay a dividend.
Navidea Biopharmaceuticals does not currently pay a dividend.
To buy shares in Navidea Biopharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Navidea Biopharmaceuticals had a market capitalisation of $0.07m.
Here are the trading details for Navidea Biopharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NAVB
Based on an overall assessment of its quality, value and momentum Navidea Biopharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Navidea Biopharmaceuticals is $5.00. That is 714185.71% above the last closing price of $0.00.
Analysts covering Navidea Biopharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Navidea Biopharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -29.81%.
As of the last closing price of $0.00, shares in Navidea Biopharmaceuticals were trading -84.78% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Navidea Biopharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Navidea Biopharmaceuticals' management team is headed by:
- Alexander Cappello - CHM
- John Scott - VCH
- Michel Mikhail - OTH
- Michael Rosol - OTH
- Amit Bhalla - IND
- Malcolm Witter - IND